E2730
Phase 2Small molecule
EisaiE2730 is one of 12 small molecule programs targeting Photosensitive Epilepsy. It is currently in Phase 2.
1
Indications
4
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Photosensitive Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Tegretol
NovartisApproved
Ativan
BBausch Health Americas, Inc.
Phase 2
BGG492
NovartisPhase 2
PF-06372865
PfizerPhase 2
E2082
EisaiPhase 2
ICA-105665
PfizerPhase 2
YKP3089
SSK Life Science, Inc.
Phase 2
E2730
EisaiPhase 2
ACT-709478
Idorsia Pharmaceuticals Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics2 trials
Single Dose1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for E2730. EMBL-EBI & Wellcome Sanger Institute.
- [4]